COGNITE
15.5.2024 08:01:29 CEST | Business Wire | Press release
Cognite, a globally recognized leader in industrial software, announced today that its flagship Industrial DataOps product, Cognite Data Fusion®, is now available on Google Cloud in Saudi Arabia. This strategic collaboration combines Cognite's leading data management and secure, trustworthy artificial intelligence (AI) with Google Cloud's powerful infrastructure and data analytics capabilities, enabling customers to seamlessly migrate their data to the cloud, ensuring scalability, flexibility, and security while empowering customers in Saudi Arabia with simple access to their complex industrial data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513716575/en/
Cognite Data Fusion® Now Available on Google Cloud in Saudi Arabia (Graphic: Business Wire)
Cognite Data Fusion will deploy its own comprehensive contextualization and generative AI (gen AI) capabilities purpose-built for complex industrial data on top of Google Cloud's advanced AI and machine learning tools—a powerful combination to deliver actionable insights, improve operational efficiency, and drive digital transformation across industries such as energy, manufacturing, and logistics.
"We are thrilled to bring Cognite Data and AI offerings to Google Cloud customers in Saudi Arabia," said Dr. Francois Laborie, Executive Vice President, Cognite. "This is a significant milestone in our partnership, and as well as our commitment to the Kingdom. The power of data and AI, from Cognite and Google Cloud, enables industry transformation via solutions that deliver business value to our customers."
"We are excited to partner with Cognite to bring their advanced industrial data platform to Google Cloud customers in Saudi Arabia," said Abdul Rahman Al Thehaiban, Managing Director, Middle East, Turkey and Africa, Google Cloud. "By leveraging Google Cloud's scalable and secure infrastructure, Cognite Data Fusion will enable customers to harness the power of their data to make smarter business decisions and accelerate their digital transformation journey."
Cognite Data Fusion’s best-of-breed gen AI capabilities tailored for industrial use cases enable customers to generate synthetic data, simulate scenarios, and optimize operations, ultimately improving decision-making and business outcomes.
In the Kingdom and the wider MENA region, Cognite Data Fusion is brought to the market by CNTXT, a joint venture between Saudi Aramco and Cognite. This partnership combines CNTXT's deep understanding of the regional industrial landscape with Cognite's cutting-edge technology, providing customers with tailored solutions that address their specific needs and challenges. "Cognite Data Fusion is poised to revolutionize how the Kingdom’s industries harness insights from their data. Cognite Data Fusion offers world-leading gen AI capabilities tailored for industrial sectors", said Abdullah Jarwan, CEO of CNTXT.
Cognite Data Fusion on Google Cloud is now available for customers in Saudi Arabia. For more information, visit www.cntxt.com.
About CNTXT:
CNTXT, a joint venture between Saudi Aramco and Cognite, is a leading digital transformation company headquartered in Riyadh, Saudi Arabia. With a mission to empower organizations through technology and innovation, CNTXT leverages strategic partnerships and a network of resellers to accelerate digital transformation across public and private sectors in the Kingdom.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power and renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable and more profitable. Cognite provides a user-friendly, secure, and scalable industrial DataOps platform, Cognite Data Fusion®, that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X (Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513716575/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom